Lv72
4560 积分 2020-12-21 加入
[Consensus on the management of liver injury associated with targeted drugs and immune checkpoint inhibitors for hepatocellular carcinoma ( version 2024)]
22小时前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
7天前
已完结
Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma
27天前
已完结
Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway
27天前
已完结
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
1个月前
已完结
Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus
1个月前
已完结
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
1个月前
已完结
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
1个月前
已完结
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
1个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
1个月前
已完结
皖公网安备34019202002308
